公开(公告)号：EP4286376A1

公开(公告)日：2023-12-06

申请号：EP22781692.3

申请日：2022-04-01

申请人： Therapex Co., Ltd. ,  Industry-Academic Cooperation Foundation, Yonsei University

发明人： SIM, Tae Bo ,  CHO, Byoung Chul ,  CHO, Han Na ,  SENGUPTA, Sandip ,  MALLA REDDY, Gannarapu ,  KIM, Young Hoon

IPC分类号： C07D401/12 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14

摘要： The present invention relates to a pharmaceutical composition for preventing and treating a cancer disease, including lung cancer, caused by abnormal cell growth containing a novel trisubstituted pyrimidine derivative with inhibitory activity against protein kinases, including EGFR, and a pharmaceutically acceptable salt thereof as active ingredients. The novel compound of the present invention has strong inhibitory activity against protein kinases. Particularly, the novel compound of the present invention has potent inhibitory effects against various drug-resistant EGFR mutants (including exon 19 deletion-T790M-C797S-EGFR, L858R-T790M-C797S-EGFR, exon 19 deletion-T790M-EGFR, and L858R-T790M-EGFR) and is useful as a prophylactic and therapeutic agent for cancer diseases caused by these EGFR mutants.